Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
NRIX
NRIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest NRIX ETF News Today | Earnings, Events & Price Alerts
NRIX News
Redmile Group Acquires Additional Shares of Nurix Therapeutics
Feb 22 2026
Fool
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares
Feb 22 2026
NASDAQ.COM
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
Feb 22 2026
Yahoo Finance
Wall Street Analysts Adjust META Stock Outlook
Jan 29 2026
Benzinga
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
Jan 21 2026
Benzinga
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
Jan 14 2026
Newsfilter
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
Jan 14 2026
PRnewswire
Evercore ISI Upgrades Roku to Outperform, Raises Price Target to $145
Jan 08 2026
CNBC
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 24 2025
Globenewswire
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Nurix Reports Bexobrutideg Clinical Data with 83% ORR in CLL Patients
Dec 06 2025
Globenewswire
Nurix Reports Bexobrutideg Clinical Data with 83% ORR in CLL Patients
Dec 06 2025
Newsfilter
Nurix Therapeutics to Host Webcast on December 8 to Review BTK Degrader Clinical Data
Dec 01 2025
Globenewswire
Nurix Therapeutics Welcomes Esteemed Biopharmaceutical Executive Roger Dansey, M.D., to Its Board of Directors
Nov 10 2025
Newsfilter
Nurix Therapeutics Unveils New Translational Findings from First Human Clinical Trial of Oral CBL-B Inhibitor NX-1607, Highlighting Immune Activation and Tumor Microenvironment Changes
Nov 07 2025
Newsfilter
Insights from 13 Analysts on Nurix Therapeutics
Nov 04 2025
Benzinga
Show More News
